Value-added medicines firm Hyloris has raised €15m from new and existing investors through a private equity offering of nearly one million new shares.

Hyloris expects to expand its portfolio to around 30 candidates by 2024, bolstered by €50m in cash and cash equivalents as of the end of 2021.

Value-added medicines specialist Hyloris has struck a deal worth up to €4.3m with Purna Female Healthcare to develop a treatment for vulvovaginal candidiasis that combines miconazole and domiphen bromide.

With an annual growth of almost 5%, the market for vascular access site repair products is attracting companies with innovative new products. Wider acceptance of new approaches to wound closure by interventionalists and the under-penetration in emerging Asian markets in particular are resulting in an uptake in the use of higher-tech devices and the emergence of local manufacturers.